Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study investigating the analgesic efficacy and tolerability outcomes of bupivacaine given as an extended release formulation compared with an immediate release formulation for the prevention of postoperative pain in patients undergoing inguinal hernia repair.

Trial Profile

Clinical study investigating the analgesic efficacy and tolerability outcomes of bupivacaine given as an extended release formulation compared with an immediate release formulation for the prevention of postoperative pain in patients undergoing inguinal hernia repair.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Pacira BioSciences

Most Recent Events

  • 15 Dec 2010 According to a Pacira Pharmaceuticals Inc media release, the US FDA has accepted the NDA for Exparel [bupivacaine] for the treatment of postoperative pain.
  • 18 Dec 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top